A Clinical Trial to study the effect of a Unani formulation in patient of Ulcers in stomach and intestine

Therapeutic Evaluation of Unani Formulation in Peptic Ulcer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/09/009776

Enrollment

Registered

2017-09-14

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- PEPTIC ULCER AND EROSION

Interventions

Intervention1: UNANI FORMULATION: Intervention Unani formulation Ingredients: 1. Sibr Aloe barbadensis 2. Anzaroot Astragalus sarcocolla 3. Kundur B

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age group 20-70 years of age. 2. Haemodynamically stable and diagnosed patients with the complaining of abdominal pain, epigastric tenderness, epigastric burning, early satiety, nausea and vomiting as main complaint. 3. Confirmed by upper GIT Endoscopy

Exclusion criteria

Exclusion criteria: 1. Patients below 20 and above 70 years of age 2. Haemetemsis and malena 3. Severe respiratory diseases 4. Severe cardiovascular diseases 5. Severe renal diseases 6. Pregnant and lactating women. 7. Patients having malignancy 8. Patient who do not willing to participate in study.

Design outcomes

Primary

Measure	Time frame
Mean number and size of ulcer / erosion before and end of treatment (after 30 days)Timepoint: after 30 days	—

Secondary

Measure	Time frame
Visual Analogue Scale / VAS for assessment of pain relief 5 Point Likert Scale for assessment of pain overall symptom relief Timepoint: 30 days	—

Countries

India

Contacts

Public ContactMohamed Hafeel

National Institute of Unani Medicine

dr.mobeen@rediffmail.com8123143721

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026